Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker.
Ahead of the planned spin-off of its Bausch + Lomb division,Bausch Health Companies Inc. is seeking to expand its eyecare therapy offerings, paying $10m up front for an option to license a Phase II integrin-targeting oligopeptide for dry age-related macular degeneration (AMD) discovered and being developed by privately held Allegro Ophthalmics, LLC. The deal gives Bausch option rights to Allegro’s full pipeline of ophthalmology candidates, including Luminate (risuteganib), in Phase II for dry AMD
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?